[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578002":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Duke University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with primary UTUC (upper tract urothelial carcinoma)","Urine DNA samples will be quantified using Bladder CARE™ at baseline, 3 months, and 6 months.",[12],"Diagnostic Test: Bladder CARE™",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Bladder CARE™","Urine methylation biomarker test",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Michael Abern, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Alireza Ghoreifinejadian, M.D.","CONTACT","919-684-8111","alireza.ghoreifi@duke.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Durham","North Carolina","27710","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-78.89862,35.99403,{"lat":42,"lon":41},[45,46,48],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":47,"role":23,"phone":19,"phoneExt":19,"email":19},"Michael Abern, M.D.",{"name":26,"role":49,"phone":19,"phoneExt":19,"email":19},"SUB_INVESTIGATOR",{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100578002","urine-methylation-markers-in-utuc-100578002",false,"NCT06805630","Urine Methylation Markers in UTUC","Urine-based Methylation Markers in the Diagnosis and Surveillance of Upper Tract Urothelial Carcinoma","Inclusion Criteria:\n\n* \\>=18 years\n* Primary UTUC\n\nExclusion Criteria:\n\n* Patients who do not understand and\u002For are unwilling to sign a written informed consent","ALL","18 Years",{"count":62,"type":63},50,"ESTIMATED","INTERVENTIONAL",[66],"NA","This is a research study to measure DNA markers in the urine of patients with upper tract urothelial cancer (UTUC) before surgery and during follow-up visits. Identifying these DNA markers could improve diagnosis before surgery, help assess risk, and predict early recurrence of the cancer. Urine samples will be de-identified and sent to Pangea Laboratory LLC for analysis. The results of this test will be compared to the traditional tests in upper tract urothelial cancer, such as cells in the urine and tissue biopsy.",[69],"Upper Tract Urothelial Cancer",[71],"UTUC","2026-05-28",{"date":74,"type":75},"2026-06-01","ACTUAL",{"date":77,"type":75},"2025-05-07",{"date":79,"type":63},"2026-06-30",{"name":5,"class":6},1]